Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 5, 2025Structural HeartOpen Access

Moderate/severe TR does not reduce 30-day survival with KCCQ improvement after M-TEER versus no/mild TR.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Significant tricuspid regurgitation is prevalent in patients undergoing M-TEER, is linked to poor prognosis, and impacts surgical decision-making, but its impact on quality of life improvements needed evaluation.

Does baseline moderate/severe tricuspid regurgitation reduce the likelihood of survival with significant quality of life improvement at 30 days in patients undergoing mitral transcatheter edge-to-edge repair compared to no/mild tricuspid regurgitation?

Population

1838 patients undergoing M-TEER in a statewide registry

Comparison

Moderate/severe TR vs no/mild TR

Design

Multicenter registry-based cohort study

Follow-up

30 days

Key result

Moderate/severe baseline tricuspid regurgitation did not significantly alter 30-day survival with ≥15-point KCCQ improvement after M-TEER compared to no/mild TR (adjusted OR 0.851, p=0.177).

Authors

CBCM BrooksNDNeal DuggalMSMilan Seth

Discussion

Loading...

Member takes

Overview

TR may affect post-M-TEER QoL; leaves open whether concomitant tricuspid intervention improves patient-reported outcomes.

Study Design

Type

Cohort (n=1,838)

Multicenter

Yes

Structured PICO

Does baseline moderate/severe tricuspid regurgitation reduce the likelihood of survival with significant quality of life improvement at 30 days in patients undergoing mitral transcatheter edge-to-edge repair compared to no/mild tricuspid regurgitation?

P
Population
1,838 patients undergoing mitral transcatheter edge-to-edge repair from a multicenter registry, followed for 30 days.
E
Exposure
Mitral transcatheter edge-to-edge repair (M-TEER) in patients with moderate/severe baseline tricuspid regurgitation
C
Comparator
Mitral transcatheter edge-to-edge repair (M-TEER) in patients with no/mild baseline tricuspid regurgitation
O
Outcome
Survival to 30 days with a ≥15-point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) scorecomposite

Main Result

Odds Ratio: 0.851

Absolute Event Rate: 59.6% vs 63.8%

p-value: p=0.177

Patients undergoing M-TEER experience significant improvements in quality of life at 30 days regardless of baseline tricuspid regurgitation severity, supporting the procedure's symptomatic benefit even in this higher-risk subgroup.

Cite This Study

Brooks et al. (2025) conducted a cohort in Mitral transcatheter edge-to-edge repair (M-TEER) (n=1,838). Moderate/severe baseline tricuspid regurgitation vs. No/mild baseline tricuspid regurgitation was evaluated on Survival to 30 days with a ≥15-point improvement in KCCQ score (adjusted OR 0.851, p=0.177). Moderate/severe baseline tricuspid regurgitation did not significantly alter 30-day survival with ≥15-point KCCQ improvement after M-TEER compared to no/mild TR (adjusted OR 0.851, p=0.177).

synapsesocial.com/papers/6a5f592fb7d7f004ae591b99https://doi.org/10.1016/j.shj.2024.100408
View Full Paper
Ask AI
Bookmark
Share